Sun, Aug 31, 2014, 6:07 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • rehdvm2004 rehdvm2004 Jan 21, 2014 10:13 AM Flag

    The key position for the future . . .

    Is the Senior Scientist who will be investigation new formulations using the liposome delivery system, per:

    "The Scientist/Sr. Scientist will be engaged in the development of lipid-based nanoparticle formulations and analyzing them using physical-chemical, photometric methods, liquid chromatography, microscopy, particle size and z-potential analysis.


    ◾Plan, design and implement experiments to develop novel formulations
    ◾Prepare lipid-based nanoparticle formulations
    ◾Characterize formulations using appropriate analytical techniques,

    such as, but not limited to HPLC, optical and fluorescent spectroscopy, particle size assessment, zeta potential, and pH)
    ◾Perform calibration and maintenance of the laboratory equipment"

    These experiments will make INSM the $billion company that pumpers have been boasting for years. However, it will take years to get these new formulations through preclinical safety and clinical safety/efficacy trials.

    BTW, the duck is not wrong on the time for the regulatory pathway to be completed. Key among the other positions being recruited is the Director of QA who will be responsible for validating and guaranteeing Arikace batches from every manufacturing site globally. But blather on about how approval will come this year. The clinical trial that can leap-frog into rapid approval world wide is NTM. But if NTM is effective, that means that patients with NTM infections will not be treated 28 days on, 28 days off for a year. It is a much different Rx scenario than the immediate $billion market touted by posters on this MB.

    Sentiment: Strong Buy

 
INSM
13.93+0.11(+0.80%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.